Fig. 7
In vivo antimetastatic mechanism of IGBN. a Cu2+ and b E2 content in tumor tissue of 4T1 tumor-bearing mice on day 14 after different treatments (n = 5). c Qualitative Western blot data of GAPDH, Capn4 and MMP-2 in tumor tissue from 4T1 tumor-bearing mice on day 14 after treatment (upper panel), (n = 3). Corresponding gray analysis of Capn4 and MMP-2 from Western blot by Image J (lower panel), (n = 3). d Immunohistochemistry images of Capn4 in tumor tissue from 4T1 tumor-bearing mice on day 14 after treatment. Scale bars: 100 μm. e Immunofluorescence staining images of MMP-2 in tumor tissue from 4T1 tumor-bearing mice on day 14 after treatment. Scale bars: 50 μm. f Immunofluorescence staining images of NO. Scale bars: 50 μm. g Immunofluorescence staining images of ROS. Scale bars: 50 μm. h Immunohistochemistry staining images of P-selectin and i TGF-β. Scale bars: 50 μm. j Immunofluorescence staining images of E-cadherin and N-cadherin. Scale bars: 50 μm. Results are presented as means ± s.d. Statistical significance was calculated by Student’s t-test. *p < 0.05, **p < 0.01 and ***p < 0.001